MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3899/jrheum.110271

Медицинская библиотека · The Journal of rheumatology · 2011

Patient-reported outcomes in chronic gout: a report from OMERACT 10.

Singh Jasvinder A, Taylor Will J, Simon Lee S, Khanna Puja P, Stamp Lisa K, McQueen Fiona M, Neogi Tuhina, Gaffo Angelo L, Becker Michael A, MacDonald Patricia A, Dabbous Omar, Strand Vibeke, Dalbeth Nicola D, Aletaha Daniel, Edwards N Lawrence, Schumacher H Ralph

Consensus StatementСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

To summarize the endorsement of measures of patient-reported outcome (PRO) domains in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10).

METHODS

During the OMERACT 10 gout workshop, validation data were presented for key PRO domains including pain [pain by visual analog scale (VAS)], patient global (patient global VAS), activity limitation [Health Assessment Questionnaire-Disability Index (HAQ-DI)], and a disease-specific measure, the Gout Assessment Questionnaire version 2.0 (GAQ v2.0). Data were presented on all 3 aspects of the OMERACT filters of truth, discrimination, and feasibility. One PRO, health-related quality of life measurement with the Medical Outcomes Study Short-form 36 (SF-36), was previously endorsed at OMERACT 9.

RESULTS

One measure for each of the 3 PRO of pain, patient global, and activity limitation was endorsed by > 70% of the OMERACT delegates to have appropriate validation data. Specifically, pain measurement by VAS was endorsed by 85%, patient global assessment by VAS by 73%, and activity limitation by HAQ-DI by 71%. GAQ v2.0 received 30% vote and was not endorsed due to several concerns including low internal consistency and lack of familiarity with the measure. More validation studies are needed for this measure.

CONCLUSION

With the endorsement of one measure each for pain, patient global, SF-36, and activity limitation, all 4 PRO for chronic gout have been endorsed. Future validation studies are needed for the disease-specific measure, GAQ v2.0. Validation for PRO for acute gout will be the focus of the next validation exercise for the OMERACT gout group.

Для цитирования: Singh Jasvinder A, Taylor Will J, Simon Lee S, Khanna Puja P, Stamp Lisa K, McQueen Fiona M, Neogi Tuhina, Gaffo Angelo L, Becker Michael A, MacDonald Patricia A, Dabbous Omar, Strand Vibeke, Dalbeth Nicola D, Aletaha Daniel, Edwards N Lawrence, Schumacher H Ralph. Patient-reported outcomes in chronic gout: a report from OMERACT 10.. The Journal of rheumatology. 2011. DOI: 10.3899/jrheum.110271.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.